BACKGROUND: To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated with first-line immunotherapy. METHODS: Baseline clinical prognostic factors, the neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour cell expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis of 784 patients divided between statistically powered training (n = 201) and validation (n = 583) cohorts. Cut-offs were explored by receiver operating characteristic (ROC) curves and a risk model built with validated independent factors by multivariate analysis. RESULTS: NLR < 4 was a significant prognostic factor in both cohorts (P < 0.001). It represented 53% of patients in the validation cohort, with 1-year overall survival (OS) of 76.6% versus 44.8% with NLR > 4, in the validation series. The addition of PD-L1 ≥ 80% (21% of patients) or LDH < 252 U/l (25%) to NLR < 4 did not result in better 1-year OS (of 72.6% and 74.1%, respectively, in the validation cohort). Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 [P < 0.001, hazard ratio (HR) 2.04], pretreatment steroids (P < 0.001, HR 1.67) and NLR < 4 (P < 0.001, HR 2.29) resulted in independent prognostic factors. A risk model with these three factors, namely, the lung immuno-oncology prognostic score (LIPS)-3, accurately stratified three OS risk-validated categories of patients: favourable (0 risk factors, 40%, 1-year OS of 78.2% in the whole series), intermediate (1 or 2 risk factors, 54%, 1-year OS 53.8%) and poor (>2 risk factors, 5%, 1-year OS 10.7%) prognosis. CONCLUSIONS: We advocate the use of LIPS-3 as an easy-to-assess and inexpensive adjuvant prognostic tool for patients with PD-L1 ≥ 50% aNSCLC.

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer / Banna, G. L.; Cortellini, A.; Cortinovis, D. L.; Tiseo, M.; Aerts, J. G. J. V.; Barbieri, F.; Giusti, R.; Bria, E.; Grossi, F.; Pizzutilo, P.; Berardi, R.; Morabito, A.; Genova, C.; Mazzoni, F.; Di Noia, V.; Signorelli, D.; Gelibter, A.; Macerelli, M.; Rastelli, F.; Chiari, R.; Rocco, D.; Gori, S.; De Tursi, M.; Di Marino, P.; Mansueto, G.; Zoratto, F.; Filetti, M.; Montrone, M.; Citarella, F.; Marco, R.; Cantini, L.; Nigro, O.; D'Argento, E.; Buti, S.; Minuti, G.; Landi, L.; Guaitoli, G.; Lo Russo, G.; De Toma, A.; Donisi, C.; Friedlaender, A.; De Giglio, A.; Metro, G.; Porzio, G.; Ficorella, C.; Addeo, A.. - In: ESMO OPEN. - ISSN 2059-7029. - 6:2(2021), p. 100078. [10.1016/j.esmoop.2021.100078]

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

Tiseo M.;Buti S.;
2021

Abstract

BACKGROUND: To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated with first-line immunotherapy. METHODS: Baseline clinical prognostic factors, the neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour cell expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis of 784 patients divided between statistically powered training (n = 201) and validation (n = 583) cohorts. Cut-offs were explored by receiver operating characteristic (ROC) curves and a risk model built with validated independent factors by multivariate analysis. RESULTS: NLR < 4 was a significant prognostic factor in both cohorts (P < 0.001). It represented 53% of patients in the validation cohort, with 1-year overall survival (OS) of 76.6% versus 44.8% with NLR > 4, in the validation series. The addition of PD-L1 ≥ 80% (21% of patients) or LDH < 252 U/l (25%) to NLR < 4 did not result in better 1-year OS (of 72.6% and 74.1%, respectively, in the validation cohort). Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 [P < 0.001, hazard ratio (HR) 2.04], pretreatment steroids (P < 0.001, HR 1.67) and NLR < 4 (P < 0.001, HR 2.29) resulted in independent prognostic factors. A risk model with these three factors, namely, the lung immuno-oncology prognostic score (LIPS)-3, accurately stratified three OS risk-validated categories of patients: favourable (0 risk factors, 40%, 1-year OS of 78.2% in the whole series), intermediate (1 or 2 risk factors, 54%, 1-year OS 53.8%) and poor (>2 risk factors, 5%, 1-year OS 10.7%) prognosis. CONCLUSIONS: We advocate the use of LIPS-3 as an easy-to-assess and inexpensive adjuvant prognostic tool for patients with PD-L1 ≥ 50% aNSCLC.
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer / Banna, G. L.; Cortellini, A.; Cortinovis, D. L.; Tiseo, M.; Aerts, J. G. J. V.; Barbieri, F.; Giusti, R.; Bria, E.; Grossi, F.; Pizzutilo, P.; Berardi, R.; Morabito, A.; Genova, C.; Mazzoni, F.; Di Noia, V.; Signorelli, D.; Gelibter, A.; Macerelli, M.; Rastelli, F.; Chiari, R.; Rocco, D.; Gori, S.; De Tursi, M.; Di Marino, P.; Mansueto, G.; Zoratto, F.; Filetti, M.; Montrone, M.; Citarella, F.; Marco, R.; Cantini, L.; Nigro, O.; D'Argento, E.; Buti, S.; Minuti, G.; Landi, L.; Guaitoli, G.; Lo Russo, G.; De Toma, A.; Donisi, C.; Friedlaender, A.; De Giglio, A.; Metro, G.; Porzio, G.; Ficorella, C.; Addeo, A.. - In: ESMO OPEN. - ISSN 2059-7029. - 6:2(2021), p. 100078. [10.1016/j.esmoop.2021.100078]
File in questo prodotto:
File Dimensione Formato  
BANNA et al, LIPS core ESMO open 2020.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 489.9 kB
Formato Adobe PDF
489.9 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2901104
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 25
social impact